Jci_page_head_homepage_01 Jci_page_head_homepage_02
Christopher H. Parsons, Laura A. Adang, Jon Overdevest, Christine M. O’Connor, J. Robert Taylor, David Camerini, Dean H. Kedes
Published in Volume 116, Issue 7
J Clin Invest. 2006; 116(7):1963–1973 doi:10.1172/JCI27249
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 1
Sequential increases in KSHV genomic DNA, latent (ORF73) and lytic (ORF50 and ORF65) transcripts within the spleens of KSHV-injected NOD/SCID mice.

Mice were administered 3 weekly doses of KSHV (squares, solid lines) or UV-KSHV (triangles, dashed lines) intravenously and euthanized 1 day (DNA only) and 1, 2, and 4 months following the third injection. (A) Genomic KSHV DNA values were determined using qPCR to calculate the ΔCt, representing KSHV Ct normalized to mouse GAPDH Ct (mean of triplicate determinations for each) for each sample. (BD) Total splenic RNA was subjected to qRT-PCR using primers specific for ORFs 73 (B), 50 (C), and 65 (D) as well as mouse GAPDH. ΔδCt = (ΔCt(G)) – (ΔCt(K)), where ΔCt(K) and ΔCt(G) are the differences between the Ct of each sample (mean of duplicate determinations) without and with reverse transcriptase (RT) for KSHV (K) and GAPDH (G), respectively. Each symbol represents the mean and SE of ΔCt (A) or ΔδCt (BD). Numbers of mice are indicated in parentheses. Graph-wide dotted lines mark the lower limit of sensitivity of each assay. Of note, UV-KSHV did not establish infection within either primary dermal microvascular endothelial cells (pDMVECs) or HeLa cells in vitro (not shown).